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Dopamine and serotonin (5-hydroxytryptamine or 5-HT) are neu-
rotransmitters that are implicated in many psychological disorders.
Although dopamine transmission in the brain has been studied
extensively in vivo with fast scan cyclic voltammetry, detection of
5-HT using in vivo voltammetric methods has only recently been
established. In this work we use two carbon-fiber microelectrodes
to simultaneously measure dopamine release in the nucleus
accumbens and 5-HT release in the substantia nigra pars reticulata,
using a common stimulation in a single rat. We find that 5-HT
release is profoundly restricted in comparison with dopamine
release despite comparable tissue content levels. Using physiolog-
ical and pharmacological analysis, we find that 5-HT transmission is
mostly sensitive to uptake andmetabolic degradationmechanisms.
In contrast, dopamine transmission is constrained by synthesis and
repackaging. Finally, we show that disruption of serotonergic
regulatory mechanisms by simultaneous inhibition of uptake and
metabolic degradation can have severe physiological consequences
that mimic serotonin syndrome.
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selective serotonin reuptake inhibitor
Dopamine and serotonin (5-hydroxytryptamine or 5-HT) areneurotransmitters with important, conserved roles in the
vertebrate nervous system. Dopamine is important in neuronal
circuitry that controls reward and in brain regions that regulate
movement (1). Assigning a specific functional role to 5-HT has
proven more difficult because electrophysiological recordings of
5-HT neurons reveal unchanged firing in response to most stimuli
(2). Competing roles have been suggested for dopamine and
5-HT in reward circuitry, with dopamine signals predicting posi-
tive stimuli and 5-HT signals predicting negative consequences
(3, 4). Biochemically, their regulation is quite similar, with similar
proteins regulating synthesis, storage, release, uptake, and me-
tabolism. To compare functional dopamine and 5-HT regulation
in the brain, methods have been developed to monitor dynamic
changes in their concentrations in the extracellular space.
Transient fluctuations of dopamine concentrations in the ex-
tracellular space of the nucleus accumbens core (NAc) can be
evoked by electrical stimulation of the medial forebrain bundle
(MFB) and have been characterized in the rat using in vivo
voltammetric methods (5, 6). Dopamine is easily oxidized, and
electrochemical methods such as fast-scan cyclic voltammetry
can be used for detection (7). A carbon-fiber microelectrode is
placed in the brain region of interest. The shape of the cyclic
voltammogram identifies dopamine, and its amplitude can be
used to calculate concentration. Each cyclic voltammogram can
be collected in less than 10 ms, enabling fast, repetitive acqui-
sition. Successive recordings of fluctuations in dopamine con-
centration lead to visualization of dopaminergic transmission
events with subsecond temporal resolution. This method has
shown that electrical stimulations of dopaminergic axons im-
mediately evoke dopamine release that is rapidly uptaken by the
dopamine transporter (DAT). During behavior, receipt of un-
expected rewards (8) or cues that predict reward (9) result in
transient changes in dopamine concentration. These transients
arise from the spontaneous firing of dopaminergic neurons in the
ventral tegmental area and are regulated by the same mecha-
nisms as electrically evoked release (10).
Similar subsecond characterizations of 5-HT transmission are
possible because 5-HT is also easily oxidized. However, vol-
tammetric detection of 5-HT is complicated by oxidative prod-
ucts that foul the electrode surface, lowering sensitivity and
temporal resolution (11). Furthermore, 5-hydroxyindole acetic
acid (5-HIAA), the primary metabolite of 5-HT, can similarly
degrade the electrode surface. To minimize these issues, we have
modified the detection waveform to prevent formation of oxi-
dation products that foul the electrode surface. We also elec-
trodeposit Nafion, a cation exchange polymer, on the carbon
fiber to decrease sensitivity to 5-HIAA (12, 13). Using these
modifications, we have demonstrated that stimulated 5-HT re-
lease can be measured in the substantia nigra pars reticulata
(SNr) by stimulating the MFB (14) at a location that also evokes
dopamine release (5).
This work characterizes and compares factors that regulate
extracellular concentrations of 5-HT and dopamine. In-house
hardware and software developments enable application of two
different waveforms at separate electrodes in different brain
regions (15). Using simultaneous dopamine and 5-HT meas-
urements evoked by a common stimulation, physiological and
pharmacological manipulations of release amplitude and uptake
properties were evaluated. We find that distinctly different
processes govern dopamine and 5-HT dynamics. Taken together,
these results show that mechanisms controlling 5-HT in the ex-
tracellular space are more stringent than those of dopamine.
Results
Simultaneous Dopamine and 5-HT Release Evoked by a Common
Stimulation. A carbon-fiber microelectrode was placed in the
NAc of each rat, and the dopamine waveform was applied. A
second microelectrode was placed in the ipsilateral SNr and used
the 5-HT waveform. Both waveforms are illustrated in Fig. 1,
Left. Release was evoked in both brain regions by electrically
stimulating the ipsilateral MFB (60 Hz, 2-s duration, biphasic
pulses, 2 ms each phase, 350 μA), shown in the color plots in Fig.
1. Each color plot encodes 300 cyclic voltammograms recorded
over 30 s around the stimulation (initiated at 5 s, vertical black
line). The shape of the cyclic voltammograms (upper current–
voltage curve, Fig. 1, Left) recorded in the NAc and SNr identify
dopamine and 5-HT, respectively. Strikingly, the amplitude of
stimulated dopamine is ∼300 times greater than that of 5-HT.
The uptake rates of the neurotransmitters are more comparable.
Dopamine and 5-HT transporters follow Michaelis-Menten ki-
netics. At low concentrations the rate constant for dopamine
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uptake in the NAc (k = Vmax/Km) is ∼14 s−1 (16), and in the SNr,
it is ∼4 s−1 for 5-HT uptake (14).
We first examined dopamine and 5-HT release as a function of
the stimulating electrode’s dorsoventral position. Fig. 1, Right
shows the normalized amplitude of evoked 5-HT in the SNr and
dopamine in the NAc obtained at varying stimulating electrode
locations as it was lowered in 0.5-mm increments from −6
to −10.5 mm through the MFB. Stars indicate that significant
release was evoked in that location (P < 0.05). Both 5-HT and
dopamine release were maximal with the stimulating electrode
at −8.5 mm. The 5-HT response profile was broader, with mea-
surable release at stimulation electrode depths between 7.0 and
10.0 mm below dura, whereas dopamine could only be recorded
between 8.0 and 9.0 mm below dura.
Effect of Stimulation Parameters on Release. We varied stimulus
parameters in the MFB to examine their effects on release rel-
ative to that obtained with our maximal conditions (depth, 8.5
mm from dura, 60 Hz: 2-s duration, biphasic pulses, 2 ms each
phase, 350 μA). Dopamine and 5-HT release are both sensitive
to stimulus pulse width (5), reaching a maximum at 2 ms (Fig.
2A). Dopamine release increases with stimulus intensity up to
350 μA with 2-ms-wide pulses (17), and 5-HT responds similarly
(Fig. 2B). Stimulated dopamine release diminishes when stim-
ulations are repeated rapidly (18). Using maximal stimulation
trains repeated every minute, we found that dopamine release
decreased with consecutive stimulations, dropping to 38% ± 7%
of the maximum normalized value (n = 6, P < 0.05) after the
20th stimulation (Fig. 2C). In contrast, maximal 5-HT release did
not show signs of depletion.
Pharmacology of Synthesis, Packaging, Release, Uptake, and Metabolism.
Various aspects of dopamine transmission, including synthesis
(5), packaging (19), autoreceptor regulation of release (6), uptake
(16, 20), and metabolism (21), were characterized with pharmacol-
ogy and in vivo voltammetry. In this study we compared the dopa-
minergic and serotonergic responses to these manipulations. The
averaged predrug and drug responses of stimulated 5-HT release are
shown in Figs. 3 and 4 (Top), and the responses for dopamine to
equivalent treatments are shown immediately below (UpperMiddle).
Histograms with amplitude and t1/2 (both expressed relative to
predrug value) are displayed in Figs. 3 and 4 (Lower Middle and
Bottom), respectively. Where the response to pharmacological
treatment is significantly different from predrug, statistical signifi-
cance (P < 0.05) is noted with an asterisk. Stimulation duration is
indicated by horizontal bars below each concentration vs. time plot.
We investigated the role of synthesis on dopamine and 5-HT
release by administering NSD 1015 (100 mg kg−1), an aromatic
amino acid decarboxylase inhibitor (Fig. 3, Left). Inhibition
of decarboxylase results in accumulation of L-DOPA and 5-
hydroxytryptophan (22). Sixty minutes after NSD 1015 admin-
istration, dopamine release was reduced to 18.0% ± 4.5% of its
original amplitude (n = 6, P < 0.05). In contrast, 5-HT release
was reduced to 48.1% ± 2.8% of its pretreatment amplitude at
the same time point (n = 6, P < 0.01). There were no significant
effects of NSD 1015 on the t1/2 of dopamine or 5-HT.
Dopamine and 5-HT are both released via exocytosis from
vesicular stores. We investigated the significance of rapid vesic-
ular packaging in both systems by comparing the effects of a vesic-
ular monoamine transporter 2 (VMAT2) inhibitor, tetrabenazine
(10mg kg−1) (23, 24). Tetrabenazine significantly reduced dopamine
Fig. 1. Left: Representative color plots with potential on the y axis, time on the x axis, and the current in false color. Horizontal white dashed line was used to
construct the current vs. time traces plotted above the color plots. Stimulation onset (dashed black vertical line) and duration is represented by the blue bar
under the current vs. time traces. Insets: Cyclic voltammograms taken at the vertical white dashed lines. Right: Averaged, normalized responses recorded in
the NAc (dopamine) and SNr (5-HT) as the stimulating electrode was lowered down a vertical tract to the MFB (n = 6). Asterisks indicate normalized 5-HT
maximal release values that are significantly different from the corresponding dopamine normalized release values (P < 0.05).





















release to 6.3% ± 3.0% of its predrug value 60 min after its ad-
ministration (n = 5, P < 0.05; Fig. 3, Center). Effects on 5-HT
release were not significant (71.6% ± 8.8% of predrug value;
n = 5). However, the time delay between stimulation onset and
maximum signal increased from 2.21 ± 0.15 s to 3.52 ± 0.34 s
(n = 5, P < 0.05) after tetrabenazine administration. Tetrabena-
zine reduced dopamine release close to the limit of detection;
therefore, t1/2 analyses for statistical significance were not possi-
ble. The t1/2 of 5-HT was significantly increased, from 1.9 + 0.25 s
to 2.59 ± 0.43 s (135% ± 21% of original; n = 5, P < 0.05).
To examine autoreceptor control of release at 5-HT terminals
in the SNr, we administered methiothepin (20 mg kg−1), a non-
selective 5-HT 1a and 1b receptor antagonist (25). Stimulated
5-HT release increased to 161% ± 10% of its original (Fig. 3,
Right) (n = 6, P < 0.05). We administered raclopride, a D2 re-
ceptor antagonist, to examine the effects of autoreceptors in the
dopaminergic system (26). Raclopride (2 mg kg−1) increased
stimulated dopamine release to 184% ± 34% (n = 6, P < 0.05) of
the predrug value. Although raclopride had no significant effects
on t1/2 for dopamine, methiothepin significantly increased t1/2 for
5-HT, from 1.36 ± 0.17 s to 1.99 ± 0.24 s (n = 6, P < 0.05).
Fig. 4, Left shows the effects of inhibition of the 5-HT uptake
transporter (SERT) and DAT. SERT was inhibited with the
selective serotonin reuptake inhibitor citalopram (10 mg kg−1)
(27), whereas GBR 12909 (15 mg kg−1) was used to inhibit DAT
(28). Citalopram significantly increased stimulated 5-HT ampli-
tude, to 476% ± 134% of its original value (n = 6, P < 0.05) and
significantly increased t1/2, from 2.27 ± 0.07 s to 7.35 ± 1.46 s
(n = 6, P < 0.05). GBR 12909 significantly increased stimulated
dopamine amplitude, to 279% ± 70% of its predrug value (n = 6,
P < 0.05) and significantly increased t1/2, from 0.86 ± 0.14 s to
2.12 ± 0.2 s (n = 6, P < 0.05).
Fig. 4, Right compares the effects of monoamine oxidase (MAO)
inhibition with pargyline (75 mg kg−1) on dopamine and 5-HT–stim-
ulated release (21). 5-HT release amplitude increased to 349% ±
60%of its original value (n= 6,P< 0.05), whereas dopamine release
did not increase significantly (175.1% ± 27.3%; n = 6, P > 0.05).
There were no significant effects of pargyline on dopamine t1/2;
however, the 5-HT t1/2 significantly increased, from 1.58 ± 0.07 s to
2.97 ± 0.49 s (n = 6, P < 0.05).
SSRI and MAOI Administration. Fig. 5 shows spontaneous efflux of
dopamine (Fig. 5A) and 5-HT (Fig. 5B) occurring after re-
spiratory arrest caused by administration of citalopram (10 mg
kg−1) followed by pargyline (150 mg kg−1). The concentration of
Fig. 2. Averaged, normalized dopamine and 5-HT maximal release with (A)
variation of stimulation pulse width and (B) stimulation current amplitude
(n = 6 for each transmitter). (C) Averaged, normalized dopamine and 5-HT
responses to repeated stimulation trains (n = 6). Stimulations were 120 bi-
phasic pulses at 60 Hz, 350 μA, and 2 ms delivered once every 60 s for 20 min.
Fig. 3. Comparison of averaged responses of 5-HT in the SNr (Top; n = 5)
and dopamine in the NAc (Upper Middle; n = 6) to pharmacological in-
hibition of synthesis, packaging, and release (left to right). Synthesis was
inhibited with NSD 1015, and vesicular packaging was inhibited with tetra-
benazine. Release was increased by autoreceptor antagonists (methiothepin
for 5-HT and raclopride for dopamine). Lower Middle and Bottom: Histo-
grams of the percent change in amplitude and t1/2 induced by the drug 60
min after its administration. Asterisks on the histogram indicate a significant
change from predrug values (P < 0.05).
11512 | www.pnas.org/cgi/doi/10.1073/pnas.1201547109 Hashemi et al.
dopamine efflux at its peak averaged 37.7 ± 3.4 μM (n = 4),
whereas 5-HT efflux was significantly lower at 0.296 ± 0.080 μM
(n = 4, P < 0.001) (Fig. 5C). The time elapsed between onset and
peak of efflux also differed significantly, averaging 77 ± 4 s for
dopamine and 266 ± 50 s for 5-HT (n = 4 for each, P < 0.01)
(Fig. 5F). Fig. 5 D and E compare responses of body temperature
and heart rate between anesthetized rats that received electrical
stimulation and two injections of saline 35 min apart (n = 4,
white) or electrical stimulation followed by citalopram (T1) and
pargyline (T2) (n = 6, black). Pargyline administration coincides
with a significant decrease in body temperature (Fig. 5D) and
heart rate (Fig. 5E) that persists throughout the remainder of the
experiment (P < 0.05).
Discussion
5-HT Release Regulation Is More Stringent than for Dopamine. In this
work electrical stimulation of the MFB simultaneously evoked
dopamine release in the NAc and 5-HT release in the SNr.
Stimulation at a common site that releases different neuro-
transmitters provides a way to compare dynamic alterations in
their regulatory mechanisms (29). A particularly noteworthy
finding was that dopamine release was ∼300 times greater than
5-HT release, despite similar tissue content in the two regions
examined [90 ng/mg protein for dopamine in the NAc (16) and
21 ng mg−1 protein for 5-HT in the SNr (30)]. Thus, despite
comparable stores, the releasable pool of 5-HT in the SNr is
miniscule compared with the releasable pool of dopamine in the
NAc. Distinct storage and releasable pools for both 5-HT and
dopamine have been described (31, 32), but the large difference
in their relative size had not previously been appreciated. More-
over, we previously noted that evoked release of 5-HT in the SNr
is much lower in vivo compared with its electrically evoked release
from SNr slice preparations (14). This suggests that in vivo 5-HT
release is subject to tighter control mechanisms than both 5-HT
in slices and dopamine in vivo.
To identify possible mechanisms for these differences, we ex-
plored the effects of the electrical stimulation on the dopamine
and 5-HT axons that course through the MFB. Dopaminergic
and serotonergic fiber bundles responded similarly to the stim-
ulation parameters tested, giving greater release with wide
electrical pulses and large current amplitudes (Fig. 2). These
properties are consistent with our predictions, given that both
fibers are unmyelinated (33, 34). Varying the dorsoventral lo-
cation of the stimulating electrode revealed that 5-HT release
can be evoked over greater region than dopamine, suggesting
that serotonergic fibers have a broader topographic distribution.
However, this is not sufficient to explain the 300-fold greater
release of dopamine because even direct stimulation of seroto-
nergic cell bodies in the dorsal raphe evokes comparably low
5-HT release (14).
The disparity between 5-HT and dopamine release amplitudes
is attributed to differences in the readily releasable pool. Do-
pamine release was sensitive to repetitive application of stimu-
lation trains, exhibiting a fatigue in release that did not occur for
5-HT in the SNr. The diminished release of dopamine after re-
peated stimulations has been attributed to depletion of the re-
leasable pool (35). In contrast, some 5-HT may be stored in
dense core vesicles (36) or other compartments that do not
exocytose. This would produce effects consistent with a small
quantity of 5-HT available for release.
Dopamine Release Is Synthesis and Packaging Sensitive, Whereas
5-HT Is an Uptake/Metabolism-Controlled System. Several of the
pharmacological agents investigated in this work (Figs. 3 and 4)
inhibit the same processes in dopaminergic and serotonergic neu-
rons. For example, inhibition of aromatic amino acid decarbox-
ylase with NSD 1015 inhibits synthesis of both 5-HT and dopamine
(22). Because the preceding experiments suggest that the re-
leasable pool of dopamine is more sensitive to depletion, we
predicted that releasable 5-HT would also be less sensitive to
synthesis inhibition, and this was found to be the case. 5-HT and
dopamine are both packaged into vesicles via the action of
VMAT2 (37), and inhibition of this transporter with tetrabena-
zine resulted in a greater decrease in dopamine release than
5-HT. We propose that a smaller releasable pool contributes to
lower release amplitudes, which in turn reduces the requirement
for packaging in serotonergic terminals. This is supported by the
comparatively moderate response of 5-HT to manipulations that
affect synthesis and packaging. There was, however, a significant
increase in the t1/2 for 5-HT clearance. An increase in cytoplas-
mic 5-HT caused by VMAT2 inhibition could decrease uptake
rates by altering the concentration-dependent driving force for
SERT, a common feature of amine transporters (38). There was
a delay in the onset of 5-HT release that may be an indication of
tetrabenazine-insensitive vesicular pools, possibly dense core
vesicles, compensating for the demand on release.
After release, one fate for monoamines is metabolic degra-
dation by MAO (39). Prior work has shown that there is a small
increase in dopamine release after MAO inhibition, presumably
because repackaging into vesicles becomes more likely during
a reduction in metabolic degradation (21). However, the in-
crease in stimulated 5-HT release after MAO inhibition is
greater than threefold, indicating that serotonergic neurons have
greater regulation by MAO. Moreover, whereas MAO inhibition
had no effect on the rate of dopamine clearance, a significant
increase in the t1/2 of the 5-HT signal indicates that this treatment
caused a reduction in 5-HT reuptake rate. Similar to inhibition of
Fig. 4. Comparison of averaged responses of 5-HT in the SNr (Top; n = 5)
and dopamine in the NAc (Upper Middle; n = 6) to pharmacological in-
hibition of uptake and metabolism by MAO. Uptake was inhibited by GBR
12909 for dopamine and citalopram for 5-HT. Pargyline inhibited MAO and
is effective for both neurotransmitters. Lower Middle and Bottom: Histo-
grams displaying the percent change in amplitude and t1/2. Asterisks on the
histogram indicate a significant change from predrug values (P < 0.05).





















VMAT2, MAO inhibition could alter the driving force of SERT,
resulting in decreased rate of uptake.
Another means for extracellular regulation is uptake via trans-
porters. However, because different receptors and transporters
regulate dopamine and 5-HT release, it was necessary to admin-
ister different agents to evaluate these control points. We found
that both neurotransmitter systems were sensitive to selective
inhibition of their transporters (Fig. 4D), results consistent with
previous work (27, 40). Serotonin autoreceptors are known to
suppress 5-HT release in a manner similar to the regulation of
dopamine release by the dopamine autoreceptor in the NAc
(41–43). We used methiothepin, a nonselective 5-HT autor-
eceptor antagonist to target the multiple 5-HT autoreceptors
(44). After raclopride and methiothepin, release of dopamine
and 5-HT, respectively, was moderately increased. This suggests
that regulation by 5-HT autoreceptors is not responsible for the
differences between 5-HT and dopamine release. The increase in
the t1/2 of the 5-HT signal after methiothepin administration is
consistent with the suggestion by Daws et al. (45, 46) that 5-HT1B
autoreceptors modulate 5-HT clearance.
Disrupting 5-HT Control Mechanisms Results in Serotonin Syndrome.
Within 2.5 h of SERT and MAO inhibition respiratory arrest was
followed by spontaneous efflux of dopamine and 5-HT (Fig. 5 A
and B). Synchronized dopamine and 5-HT efflux likely reflects
reversal of their transporters, which use secondary active transport
coupled to the respiration-sensitive Na+/K+ ATPase (38). The
spontaneous efflux preceding death resembles evoked release in
that the maximum 5-HT amplitude is much lower than for dopa-
mine (Fig. 5C). Furthermore, 5-HT efflux is prolonged (Fig. 5D),
adding support to the concept that 5-HT is constrained more
tightly with neurons. After citalopram, pargyline administration
led to decreases in heart rate and body temperature, leading up to
eventual death (Fig. 5 D and E). These findings concur with pre-
vious reports that combined administration of MAO and SERT,
but not DAT, inhibitors cause fatalities in rats (47). In humans,
this pharmacological combination is known to induce serotonin
syndrome, which arises from excess serotonergic activity in the
central nervous system (48–50). Our findings reveal the con-
sequences of serotonin syndrome in anesthetized animals.
Conclusions
In prior work we used a similar comparative approach to com-
pare release of norepinephrine and dopamine evoked by a single
stimulation and found that their release and uptake character-
istics were quite similar (29). In this work, high time resolution
recordings revealed much greater differences in regulation of
dopamine and 5-HT. We found that 5-HT release is highly
regulated and is dominated primarily by reuptake/inactivation
systems that could not be unraveled with slower monitoring
techniques, such as microdialysis. Moreover, use of electro-
chemical monitoring has revealed neurochemical processes that
occur as a result of serotonin syndrome fatality.
Methods
Full experimental procedures are provided in SI Methods.
Surgical Procedures. Stereotaxic surgeries for voltammetric measurements
were performed as previously described (12). Briefly, Nafion-modified car-
bon-fiber microelectrodes were implanted in the SNr and in NAc. A bipolar
stainless steel stimulating electrode was implanted into the MFB. As noted,
heart rate, breathing, and body temperature were monitored in some ani-
mals (SI Methods).
Voltammetric Procedures. Quad Universal Electrochemical Instrument (UEI)
potentiostats described previously (15) were modified by enabling in-
dependent control of the potential on two pairs of operational amplifiers in
the head stage. A data acquisition system capable of generating two in-
dependent waveforms and collecting from two sets of channels was pre-
viously described (15). All potentials reported are against Ag/AgCl.
Drugs and Reagents. Pharmaceutical-grade pargyline hydrochloride, NSD 1015
(3-hydroxybenzylhydrazine dihydrochloride), GBR 12909 dihydrochloride, ra-
clopride, methiothepin, citalopram, and tetrabenazine were administered i.p.
Data Analysis. Two-tailed Student’s t tests were performed on paired data
sets. P < 0.05 was taken as significant. Error bars are given as ±SEM. Two-
way ANOVA was used for the analysis of body temperature and heart rate.
Fig. 5. Effects of citalopram and pargyline. (A and B) Representative results from individual animals for dopamine (NAc) and 5-HT (SNr) efflux that both occur
spontaneously immediately after respiratory arrest. (C) Maximal dopamine and 5-HT concentrations (n = 4 for each). (D) Response of body temperature
relative to baseline (0–25 min) during electrical stimulations (six 2-s stimulations, 5 min apart, ES), after citalopram (T1), and after pargyline (T2). Drug-treated
animals shown in filled circles (n = 6) and saline controls shown in open circles (n = 4). (E) Response of heart rate to electrical stimulations (ES), citalopram (T1),
and pargyline (T2). Drug-treated animals shown in filled bars (n = 4), saline controls shown in open bars (n = 4). (F) Mean time between onset of efflux and
peak of efflux for dopamine and 5-HT (n = 4). Asterisks indicate significant differences between groups (*P < 0.05; **P < 0.01; ***P < 0.001).
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